Stockreport

Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome [Yahoo! Finance]

Neurogene Inc.  (NGNE) 
PDF On track to complete dosing in Embolden™ registrational trial of NGN-401 in second quarter of 2026 Plans to present additional interim Phase 1/2 clinical data in mid- [Read more]